Kyongbo Pharmaceutical Co Ltd - Asset Resilience Ratio
Kyongbo Pharmaceutical Co Ltd (214390) has an Asset Resilience Ratio of 1.88% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Kyongbo Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Kyongbo Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kyongbo Pharmaceutical Co Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Kyongbo Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 214390 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩6.91 Billion | 1.88% |
| Total Liquid Assets | ₩6.91 Billion | 1.88% |
Asset Resilience Insights
- Limited Liquidity: Kyongbo Pharmaceutical Co Ltd maintains only 1.88% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Kyongbo Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Kyongbo Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Kyongbo Pharmaceutical Co Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Kyongbo Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.26% | ₩820.00 Million ≈ $555.70K |
₩319.54 Billion ≈ $216.55 Million |
-0.45pp |
| 2024-12-31 | 0.70% | ₩2.00 Billion ≈ $1.36 Million |
₩283.89 Billion ≈ $192.39 Million |
+0.38pp |
| 2023-12-31 | 0.33% | ₩870.00 Million ≈ $589.59K |
₩266.31 Billion ≈ $180.47 Million |
-0.03pp |
| 2022-12-31 | 0.36% | ₩870.00 Million ≈ $589.59K |
₩240.54 Billion ≈ $163.01 Million |
+0.85pp |
| 2021-12-31 | -0.49% | ₩-1.16 Billion ≈ $-786.85K |
₩236.98 Billion ≈ $160.60 Million |
-4.26pp |
| 2020-12-31 | 3.77% | ₩9.54 Billion ≈ $6.47 Million |
₩253.24 Billion ≈ $171.62 Million |
+4.21pp |
| 2019-12-31 | -0.44% | ₩-1.05 Billion ≈ $-713.64K |
₩237.82 Billion ≈ $161.17 Million |
+0.27pp |
| 2018-12-31 | -0.71% | ₩-1.58 Billion ≈ $-1.07 Million |
₩221.62 Billion ≈ $150.19 Million |
-0.07pp |
| 2017-12-31 | -0.64% | ₩-1.32 Billion ≈ $-895.45K |
₩204.87 Billion ≈ $138.84 Million |
-- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more